Related Experiment Video

Updated: Mar 29, 2026

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

902

Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors

Nitya Raj1, Diane Reidy-Lagunes1

  • 1Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 1039, New York, NY 10065, USA.

Hematology/Oncology Clinics of North America
|November 29, 2015
PubMed

Insights

Pancreatic neuroendocrine tumors (PNETs) are rare and often metastatic. This review details current systemic therapy options for advanced PNETs, aiding clinical management.

Area of Science:

  • Oncology
  • Gastroenterology
  • Endocrinology

Background:

  • Pancreatic neuroendocrine tumors (PNETs) represent 1-2% of pancreatic neoplasms.
  • PNETs are frequently diagnosed at a metastatic stage, complicating management.
  • Tumor heterogeneity and variable aggressiveness present therapeutic challenges.

Purpose of the Study:

  • To review available systemic therapy options for advanced pancreatic neuroendocrine tumors.
  • To provide an overview of current treatment strategies for PNETs.

Main Methods:

  • Literature review of systemic therapies for advanced PNETs.
  • Analysis of treatment modalities including somatostatin analogues, chemotherapy, and targeted agents.

Main Results:

  • Systemic therapies for advanced PNETs include somatostatin analogues, chemotherapy, and targeted agents.
  • Diverse treatment options exist to manage the complexity of PNETs.

Conclusions:

  • Effective management of advanced PNETs requires a comprehensive understanding of available systemic therapies.
  • Ongoing research and evolving treatment landscapes are crucial for improving patient outcomes.
Keywords:
Carcinoid tumorsEverolimusLanreotideNeuroendocrine tumorsOctreotidePancreatic neuroendocrine tumorsSunitinib

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.6K

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
479
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
748